tradingkey.logo

BRIEF-Moleculin Receives First Country Approval In Europe To Begin Recruiting For Phase 3 R/R Acute Myeloid Leukemia Trial

ReutersFeb 11, 2025 1:52 PM

- Moleculin Biotech MBRX.O:

  • MOLECULIN RECEIVES FIRST COUNTRY APPROVAL IN EUROPE TO BEGIN RECRUITING FOR THE MIRACLE PHASE 3 R/R ACUTE MYELOID LEUKEMIA (AML) PIVOTAL TRIAL

  • MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE TRIAL EXPECTED Q1 2025

Source text: ID:nPn7y6kN7a

Further company coverage: MBRX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI